- Home
- ATOS vs BEAT Comparison
ATOS vs BEAT Comparison
Compare ATOS & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATOS | BEAT |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 27.7M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATOS | BEAT |
|---|---|---|
| Price | $2.60 | $0.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $23.00 | $5.63 |
| AVG Volume (30 Days) | 49.4K | ★ 424.2K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,758.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.48 |
| 52 Week High | $7.56 | $4.00 |
Technical Indicators
Market Signals| Indicator | ATOS | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 39.82 |
| Support Level | $0.58 | $0.49 |
| Resistance Level | $6.18 | $0.79 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 85.94 | 10.78 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.